Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).

Pacemaker 52

Pacemaker Aortic Stenosis Aortic valve 52

Dr. S. Venkatesan MD

JANUARY 17, 2025

We know TAVI is in the striking distance , to literally take over most aortic valve interventions. While the numbers increase, still the debate between SAVR and TAVR is riddled with speculation, skepticism, and absolute confidence. Thanks to the hardware, expertise, and motivation from multiple forces.

TAVR 52

TAVR Aortic valve Hospital Academic 52

Circulation: Cardiovascular Interventions

MARCH 26, 2025

BACKGROUND:Current guidelines recommend surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and unfavorable iliofemoral access. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6% versus 4.3%; hazard ratio, 2.93 [95% CI, 1.455.94]).

Aortic valve 40

Aortic valve Aortic Stenosis TAVR 40

DAIC

MARCH 12, 2024

A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.

TAVR 52

TAVR Aortic valve Aortic Stenosis 52

Open Heart

JANUARY 19, 2023

Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.

Aortic valve 52

Aortic valve TAVR Aortic Myocardial Infarction 52

Journal of the American Heart Association

MARCH 21, 2025

BackgroundCurrent guidelines and expert consensus recommend lifelong single antiplatelet therapy for patients undergoing transcatheter aortic valve replacement who have no indication for anticoagulation or dual antiplatelet therapy. Journal of the American Heart Association, Ahead of Print.

Aortic valve 40

Aortic valve Aortic Myocardial Infarction TAVR 40

Dr. S. Venkatesan MD

FEBRUARY 9, 2024

Reviewing NOTION study, the Nordic TAVI 10 year follow up has just been released (Ref 1) : Caution : Non-academic content This study reports the long-term outcome in low-risk individuals who required AVR. No doubt ,the Aortic interventional world is applauding and everyone is joining the party. Now, some academic queries ?

Aortic valve 52

Aortic valve Aortic Academic Physiology 52